33 results about "Immune Dysfunction" patented technology

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases or conditions such as those which may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. In some aspects, the invention provides a synergistic combination of a prebiotics, e.g., a mixture of human milk oligosaccharides, and a probiotic strain, such as a strain capable of internalizing and consuming the rebiotics, e.g., B. longum subsp. infantis.

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

The application discloses CpG-containing oligodeoxynucleotide (ODN) with the function of regulating the body's immune capacity and application thereof. The oligodeoxynucleotide in the application is different from the design concept of traditional A-type CpG ODN in sequence and structure, embodies the complex drug-making rule and overcomes the problem of traditional A-type CPG in drug-making. The oligodeoxynucleotide has excellent activity of regulating the body's immune function in vitro and in vivo, can stimulate the production of I, II and III type interferons, regulates the Th1 type immune response, and inhibits the Th2 type and Th17 type inflammatory response. Therefore, the oligodeoxynucleotide can prevent and treat allergic diseases caused by Th2 type immune response, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophil and Th17 related diseases, can prevent and treat the infection and spread of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites, can improve the immune level of the elderly and immunodeficient population, can convert "cold tumor" into "hot tumor", improve the effect of cancer immunotherapy, can prevent and treat central nervous system diseases related to immune dysfunction such as Alzheimer's disease, and can be applied to other diseases related to immune dysfunction.

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.

The present invention relates to a novel Latilactobacillus curvatus strain WiKim0169 having immunoenhancing efficacy, and an immunoenhancing composition comprising same. In the present invention, it was found that the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, significantly increases splenic NK cell activity and increases the production of inflammatory mediators, immunoglobulins, and cytokines, thereby alleviating immunosuppressive responses. In addition, it was confirmed that the Latilactobacillus curvatus strain WiKim0169 has an effect of alleviating immune dysfunction by increasing the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in splenic tissue and increasing the phosphorylation levels of NF-κB and IκBα. Therefore, according to the present invention, the composition comprising the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, as an active ingredient is expected to be usefully employed as a pharmaceutical and functional food composition for immunoenhancement.

The present invention discloses a method for generating thymic epithelial progenitor (TEP) cells, hematopoietic stem cells (HSCs), adult tissue progenitor / stem cells, or other progenitor cells derived from human-induced pluripotent stem cells (iPSCs) to overexpress PD-L1 and / or HLA-G. This innovative approach aims to reduce allogeneic rejection by donor immune cells in immunocompetent recipients. By enhancing the immune-modulatory properties of iPSC-derived cells through the overexpression of PD-L1 and / or HLA-G, the invention seeks to improve the engraftment and functionality of these cells. This strategy holds significant potential for restoring thymus function and inducing immune tolerance, offering therapeutic benefits for patients with thymus defects, immune dysfunction, or requiring enhanced immune tolerance for graft acceptance.

Methods are provided for detecting and correcting defective anti-tumor antibody responses by identifying Fc properties therein, enhancing such properties, and administering enhanced anti-tumor antibodies to a subject, or administering enzymes that enhance Fc properties in situ.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

The application discloses a polymer microneedle patch co-loaded with self-antigen peptides and immunomodulators and a preparation method thereof, and studies the ability of the polymer microneedle patch to reverse immune dysfunction of rheumatoid arthritis (RA). The preparation method is as follows: a biocompatible polymer matrix material and a self-antigen are dissolved in pure water, and then an immunomodulator is added to obtain a suspension by stirring. The suspension is added to a mold to form needle tips, a backing layer solution is poured after drying, and finally the microneedle patch is demolded. Animal experiments show that the microneedle has sufficient mechanical strength to deliver drugs transdermally, effectively induces tolerogenic dendritic cells at the drug delivery site, further activates the differentiation of regulatory T cells (Treg), significantly up-regulates anti-inflammatory cytokines, down-regulates pro-inflammatory cells, antibodies and cytokines, effectively restores the immune balance of rheumatoid arthritis, and finally almost completely eliminates the symptoms and inflammatory infiltrates of rheumatoid arthritis. The microneedle preparation method is simple and rapid, and has a good clinical transformation prospect.

The invention provides a composition for relieving beef cattle transportation stress syndrome and application thereof, the composition is prepared by premixing dexmedetomidine hydrochloride, gastrodin and normal saline for injection according to the mass concentration ratio, the concentration of dexmedetomidine hydrochloride is 60-65 g / mL, and the concentration of gastrodin is 20-30 mg / mL. The composition is applied to beef cattle before transportation, the composition is intramuscularly injected, and the total injection volume is 10-20 mL. After the composition is injected before beef cattle transportation, immune dysfunction can be effectively improved, excessive HPA axis activation is inhibited, cortisol secretion is reduced, oxidative damage is relieved, and the stability of intestinal flora is maintained, so that inflammation is relieved, nervous excitability is reduced, calming and anxiety resisting effects are achieved, beef cattle transportation stress response is reduced, and the beef cattle transportation effect is improved. And the method is simple to operate and low in cost, and provides theoretical and practical support for preventing the beef cattle transportation stress syndrome.

This invention relates to the biomedical field, specifically to biomarkers, kits, and their applications for assessing immune dysfunction in HIV-infected individuals. This invention discloses the application of the molecular marker SMPD1 and / or substances that detect said molecular marker in the assessment, auxiliary assessment, screening, and risk stratification of immune dysfunction in HIV-infected patients with hyperlipidemia. This invention is the first to identify an immunometabolic paralysis subtype in HIV-infected individuals with hyperlipidemia. SMPD1 expression was significantly upregulated in these subtype patients, and its high expression was significantly associated with the risk of immune reconstitution failure. A combined diagnostic model based on SMPD1 and triglycerides demonstrated excellent diagnostic efficacy. Therefore, substances that detect SMPD1 can be used for the assessment and risk stratification of immune dysfunction in HIV-infected patients with hyperlipidemia. This invention provides an effective tool for the early identification and risk stratification of these patients and has broad clinical application prospects.

Ocular surface disorders (OSDs), like dry eye disease, can have a variety of symptoms and underlying causes, so patients need personalized treatment plans. Treatment planning can include determining at least one treatment location for a non-invasive photoceutical based on at least one characteristic of the OSD. One or more photoceuticals, having one or more different parameters, can be designed based on the at least one treatment location and characteristic of the OSD to address interplay between at least two of inflammation, pain, and immune dysfunction related to the OSD. At least one treatment device (comprising at least one light source) can be selected to deliver the one or more photoceutical to the at least one treatment location to treat the OSD and at least one dose of the at least one photoceutical can be configured to be applied to at least partially treat the OSD.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases, disorders, or conditions that may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome, such as graft versus host disease (GVHD). In some aspects, the invention provides a synergistic combination of prebiotics that are synthetic or derived from human milk with a probiotic strain of bacterium, such as a strain capable of internalizing and consuming the prebiotic, e.g., Bifidobacterium longum subsp. infantis.

Disclosed herein are compositions for cleaving antibodies and in vivo methods of using these compositions. The compositions comprise recombinant enzymes having human and non-human primate IgM-specific protease activity and human and non-human primate IgG-specific protease activity, providing a means of directly addressing pathogenic IgM and IgG antibodies, which are key players in the initiation of immune dysfunction. The enzymes may comprise a sequence having at least 50% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18.

This invention relates to methods for treatment of diseases of aging including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and / or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

The invention provides multifunctional antibody-ligand traps and methods of using them to counteract immune tolerance and / or immune dysfunction. The multifunctional antibody-ligand traps and fusion proteins of the invention can counteract immune dysfunction in order to restore and unleash antitumor or pathogen-directed immune responses. Provided here are promising immunotherapeutic agents for treatment and prevention of cancers, infectious diseases, and immuno-inflammatory disorders.

The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain and uses thereof. The novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit superior CD8+ T cell activity stimulating capacity and Treg cell inhibitory activity and stimulate and improve anti-tumor immune responses through various mechanisms such as increasing macrophage infiltration in CPS tumors as well as macrophage differentiation and reprogramming into inflammatory phenotype (M1). Thus, the strain and polysaccharides derived from the strain of the present invention can be effectively used for immunomodulation, especially immune boosting, in a subject and can inhibit tumor growth by inducing and enhancing anti-tumor immune responses. The novel strain and polysaccharides derived from the strain of the present invention are useful for preventing, ameliorating or treating various immunological diseases such as tumors, infectious diseases and various immunological diseases caused by or as symptoms of immune dysfunction.

Provided are a plurality of CpG-containing oligodeoxynucleotides (ODNs) capable of regulating the immune function of the body and the use thereof. The design concept of the sequences and structures of the oligodeoxynucleotides are different from those of a traditional type-A CpG ODN, which embodies the complex druggability rules of the oligodeoxynucleotides, and solves the druggability problem of the traditional type-A CpG. The oligodeoxynucleotides have the activity of regulating the immune function of the body both in vitro and in vivo, can stimulate the production of type I, II and III interferons, up-regulate a Th1-type immune response, and suppress Th2-type and Th17-type inflammatory responses. Therefore, the oligodeoxynucleotides can be used in the prevention and treatment of allergic diseases, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary diseases, and diseases associated with eosinophilic granulocytes and Th17, caused by a Th2-type immune response; can be used in the prevention and treatment of the infection and transmission of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites; can be used to improve the immunity level of the elderly population and people with immunodeficiency; can be used to convert "cold tumors" into "hot tumors" and improve the effect of cancer immunotherapy; can be used in the prevention and treatment of central nervous system diseases associated with immune dysfunction such as Alzheimer's disease; and can be used for other diseases associated with immune dysfunction.

This invention provides 3-amino-4-(piperazin-1-yl)benzamide derivatives, pharmaceutical compositions comprising them, methods for their preparation, and applications. These compounds act as PLAGL2 protein inhibitors, playing a significant role in various diseases, including but not limited to pain, inflammation, immune dysfunction, neurological and psychiatric disorders, respiratory diseases, urinary system diseases, reproductive system diseases, embryonic developmental abnormalities, cell metabolic disorders, differentiation problems, and viral infections. PLAGL2 plays a particularly positive role in the occurrence, development, and prognosis of malignant tumors such as liver cancer, lung cancer, and glioma. The compounds of this invention exhibit excellent PLAGL2 inhibitory activity. This invention also provides the compounds comprising the pharmaceutically acceptable salts thereof, pharmaceutically acceptable carriers or excipients, and methods for their preparation.

Methods of identifying a dog as having deficient nucleic base salvage and methods of identifying a dog as being at an elevated risk and increased likelihood of developing immune dysfunction are disclosed. Methods of treating a dog to prevent, delay onset of or reduce severity of symptoms of immune dysfunction in the dog and methods of treating a dog diagnosed with or suspected of having immune dysfunction are disclosed. Methods of treating a dog diagnosed with or suspected of having immune dysfunction are disclosed. The disclosed methods include performing a genetic analysis of the dog to detect the presence of 2 copies of major allele G for single nucleotide polymorphism Affx-205876096. Nutritionally complete and balanced dog food compositions are disclosed. The nutritionally complete and balanced dog food compositions comprise a therapeutic level of nucleotides.

The invention discloses a method for promoting immune reconstruction and preventing tumors through moxibustion healing. The method mainly comprises the following steps: S1, preliminary physique evaluation and immune function evaluation; s2, making a personalized moxibustion therapy scheme; s3, a basic moxibustion therapy stage; s4, an immune activation stage; s5, a tumor susceptibility protection stage; s6, curative effect tracking and immunity re-evaluation; and S7, carrying out matched life guidance and psychotherapy healing. According to the method for promoting immune reconstruction and preventing tumors through moxibustion therapy, the activity of natural killer cells (NK) and T lymphocytes can be effectively improved; the immune function disorder, cold-dampness endogenesis and stasis toxin accumulation states of sub-health groups are improved; recurrent infection, chronic inflammation and tumor susceptibility probability are obviously reduced; the method is non-drug, personalized, suitable for long-term intervention and high in safety.

Provided is a method for treating liver immune dysfunction in a subject. Liver immune dysfunction can be induced by at least one tumor arising from metastasis in the liver or at least one primary liver cancer. An exemplary method includes administering to a subject a Toll-like receptor 9 (TLR9) agonist, for example, a TLR9 agonist having the structure: 5'-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3'. The TLR9 agonist is administered to the liver, for example, the TLR9 agonist can be administered to the liver using local therapy through the vascular system.

The invention discloses a spleen-targeted nano assembly of an active component of Sanhuang heart-fire purging decoction as well as a preparation method and application of the spleen-targeted nano assembly, and belongs to the technical field of biological medicines. The spleen-targeted nano assembly comprises a spleen-targeted cell exosome and a nano assembly containing the active component of the Sanhuang heart-fire purging decoction, the nano assembly containing the active ingredients of the Sanhuang heart-fire purging decoction is loaded on the spleen-targeted cell exosome; the active ingredients of the Sanhuang heart-fire purging decoction comprise three active ingredients corresponding to three traditional Chinese medicines, namely rheum officinale, coptis chinensis and scutellaria baicalensis. The invention has the following beneficial effects: on the basis of three key active components of the Sanhuang heart-fire-purging decoction, a nano delivery system of a carrier-free pure drug of three active components of a traditional Chinese medicine compound is developed for the first time through a chemical self-assembly technology, and support is provided for development of a new dosage form of a traditional Chinese medicine compound nano preparation; and the compound has a good targeted therapeutic effect on diseases mediated by spleen immune dysfunction.

This invention discloses a humanized Sirpα The construction methods of immunodeficient mice and their application in human immune reconstitution belong to the field of medical experimental model construction technology. Rag2 ‑ / ‑ IL2rg ‑ / ‑ Using animals with T, B, and NK cell immune dysfunction caused by mutations as the background strain, sgRNA and dsDNA were specifically designed, and their endogenous components were processed using CRISPR / Cas9 gene editing technology. Sirpα The entire genome was modified to be humanized, thus creating a humanized genome. Sirpα Immunodeficient mice. This method is simple to operate, highly reproducible, and constructs a fully humanized mouse. Sirpα Immunodeficient mice exhibit a higher immunodeficient phenotype and can achieve a higher rate of human T cell chimerism after transplantation with human peripheral blood mononuclear cells, while effectively reducing the risk of graft-host disease.

This invention discloses a quinolinate phosphoribosyltransferase (quinolinate phosphoribosyltransferase) intestinal function improvement product and its preparation method. The quinolinate phosphoribosyltransferase intestinal function improvement product includes quinolinate phosphoribosyltransferase. Based on the data from the test cases, it can be seen that oral administration of the quinolinate phosphoribosyltransferase intestinal function improvement product can intervene in the intestinal quinolinate phosphoribosyltransferase level, enhance the intestinal mucosal barrier function, maintain normal intestinal permeability, and alleviate intestinal immune dysfunction and intestinal inflammation.

Compounds having the general formula (I), in particular compounds having the formula (II), as described and defined herein, processes for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds, and the use of the compounds and pharmaceutical compositions as separate agents or in combination with other active ingredients for the treatment or prevention of diseases, such as, for example, diseases, such as, for example, diseases. The present invention relates to the use of such conditions, in particular cancer or immune dysfunction conditions or other conditions associated with aberrant AhR signaling. # imgabs0 #

The present invention provides an antibody or a functional fragment thereof that specifically binds to IL-17A with high affinity. Also provided are a nucleic acid molecule encoding the antibody or the functional fragment thereof disclosed herein, an expression vector and a host cell for expressing the antibody or the functional fragment thereof disclosed herein, and a method for preparing the antibody or the functional fragment thereof disclosed herein. The present invention also provides a pharmaceutical composition comprising the antibody or the functional fragment thereof disclosed herein, and use of the antibody or the functional fragment thereof disclosed herein for treating an immune dysfunction disease.